P/B
9,1
Moderna
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
$61.5B
Market Cap • 9/18/2026
2016
(10 years)
Founded
2018
(8 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
S&P500 Participant
Index Composite • 2026
Valuation
P/S
27,6
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
17,2
EPS
—
Market Cap
Market Cap
61,5B
EV
57,6B
EV/Revenue
25,9
EV/EBITDA
-18,7
EV/EBIT
-17,3
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-0,1%
Total Yield
-0,1%
Payout
0%
Retained Earnings
5,1B
Profitability
Gross Margin
23,4%
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
129,1%
Capex/Revenue
7,7%
Capex/D&A
71%
Capex/OCF
-15,9%
SBC/OCF
—
% PPE
25,1%
% Goodwill
0%
ROE
—
ROIC
—
Growth
CAGR Revenue 5Y
-20,5%
Leverage
N.D./EBITDA
1,3
Debt/Equity
0%
Current Ratio
2,3
Quick Ratio
2
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!